Treatment with immunotherapy is tied to a lower risk for relapse in patients with myelin oligodendrocyte glycoprotein antibody disease (MOGAD), new research shows.
A large-scale analysis has revealed few biological and prognostic differences between HER2-low and HER2-negative breast cancer, and they should not be treated differently, say clinicians.
First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).